The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
A new report on strategic account manager (SAM) compensation found that SAM roles continue to grow in importance. Key indicators include the large percentage of future growth companies expect from their strategic accounts and increased investment that companies are making in their SAM programs. Strategic account management is a company-wide initiative in complex, highly matrixed organizations that focuses on building strong and mutually beneficial relationships with a firm's most important customers and partners.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64374-sama-zs-associates-strategic-account-manager-programs
Hundreds of CEOs from the healthcare, biotech and pharmaceutical industries plan to huddle next month with investment professionals to seek new business models to bridge healthcare’s gap between innovation and financial resources. They will be meeting at the 2nd Annual Global Leaders Healthcare Forum, in San Francisco on January 10, 2012. The forum is hosted by The Global Leaders, an exclusive business network of 2 million CEOs and other senior executives worldwide.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53879-the-global-leaders-healthcare-forum-san-francisco-2011
CPhI Worldwide, organised by UBM Live, celebrates the closing of its most successful show to date with pre-audit figures estimating more than 34,000 attendees and 2,200 exhibitors. Held in Frankfurt, the show hosted senior-level decision makers and key players from 140+ countries representing every step of the pharmaceutical supply chain from drug discovery to finished dosage.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/63503-UBM-live-cphi-worldwide
ACG – the leading partner for pharmaceutical industry’s myriad requirements – is strengthening its product portfolio by launching several new machines at CPhI/P-MEC India, to be held during 2-4 December 2014, at Bombay Exhibition Centre, Mumbai.
P-MEC India, co-located with CPhI India, is one of the ‘must-attend’ events in the international pharmaceutical industry. With a booth that spreads over 1,000 sq. m., ACG will be displaying several new machines including the all-new ACG X.One Technology that reinvents the 12-bar safety features; Protab, a tablet press suited for small to medium batch sizes, and many more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391551-ACG-Launch-New-Machines-at-CPhI/
A new national survey released today shows large percentages of science teachers and parents strongly agree that demonstrating real-life applications in science (87 percent and 72 percent, respectively) can help make science education more interesting for U.S. students. Almost all science teachers (99 percent) and nine in ten parents (90 percent) feel that science education is important, if not very important for a child’s future, but that it needs to be more engaging to capture the attention of children in America today (97 percent and 96 percent, respectively). The survey, conducted online by Harris Interactive on behalf of iBIO Institute and Astellas Pharma US, Inc. (“Astellas”) included a sample of 235 science teachers and 300 parents with school-age children in kindergarten through 12th grade.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/astellas/46023/
Raising public awareness of peripheral neuropathic pain (PNP), The Pain Within is a touring exhibition of major European cities which launched today at the 7th congress of the European Federation of IASP Chapters (EFIC) in Hamburg. Top photographer Alex Telfer has worked with patients to capture their experiences in both portraits and visual metaphors for the exhibition, which is sponsored by Astellas Pharma Europe Ltd. It will then tour in other countries in Europe.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellastrade/52120/
Astellas Pharma Europe Ltd. today presented The Economist Innovation 2011 award for Bioscience to one of the world’s most influential biomedical engineers, Dr Robert Langer – the man responsible for founding the field of controlled-release drug delivery and tissue engineering.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellaspharma/52158/
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
CPhI Worldwide, organised by UBM EMEA, formally launches a new partnership with international charity Global Angels, to help promote its efforts and encourage support from the pharmaceutical industry.
The goal is to harness CPhI’s global reach to actively deliver support and funds from inside the pharma industry to Global Angels – a charity that partners with innovative projects to deliver tangible, life saving results in developing countries.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7522851-cphi-agreement-global-angels/
Seeking to support men and their loved ones facing the challenges that come with a diagnosis of prostate cancer, USA Rugby, the Australian Rugby Union and Astellas Pharma have partnered to launch the #pass4prostate challenge, a social media campaign designed to generate awareness of prostate cancer and support a donation of up to $125,000 from Astellas to four research and advocacy organizations: Prostate Cancer Foundation, Australia Prostate Cancer Research, Prostate Cancer Foundation Australia and Prostate Cancer Canada.
From August 5 through the end of September – Prostate Cancer Awareness Month – social media users are encouraged to record a video of themselves catching an inanimate object, mentioning why prostate cancer awareness is important to them, and then passing that object, rugby-style, symbolically to a friend or family member. Astellas will donate $5 to prostate cancer advocacy organizations for every qualifying submission with the #pass4prostate hashtag posted to Facebook, Twitter or Instagram, up to a maximum contribution of $125,000.
To view the multimedia release visit:
http://www.multivu.com/players/English/7579051-pass4prostate-challenge-rugby-astellas/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
